Alemtuzumab is now approved in England (from 28 May 2014) and Scotland (7 July 2014) as a treatment for adults with active relapsing remitting multiple sclerosis on the NHS (by NICE and the Scottish Medicines Consortium respectively). This liberal approval represents a significant change in the way drugs for multiple sclerosis are approved; responsibility for deciding who gets alemtuzumab is being handed over to patients and their doctors. People with relapsing-remitting multiple sclerosis now have the option of an aggressive therapy early in their illness. This is not for everyone, and we urge caution on the behalf of doctors and patients considering alemtuzumab treatment. But we are pleased this is now an option.Alemtuzumab is now also licensed in Canada, Argentina, Australia, Brazil and Mexico. News from the United States is that Genzyme have resubmitted their application for a licence for alemtuzumab to the FDA, dropping their appeal at the same time. This is a positive move on behalf of the regulator and the company.For our latest publication on the long-term effects of alemtuzumab, see here.
Trials in multiple sclerosis
Wer are still actively recruiting for a trial of alemtuzumab in relapsing-remitting multiple sclerosis (”CAMTHY”) in the UK. More information on this trial can be found here:for people with multiple sclerosisfor doctorsAlasdair ColesAugust 2014